West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$239.26 USD
0.00 (0.00%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $239.18 -0.08 (-0.03%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
WST 239.26 0.00(0.00%)
Will WST be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for WST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for WST
OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
WST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Teladoc Health Q2 Loss Narrower Than Expected on Declining Expenses
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised
Other News for WST
Altria Among 6 Dividend Kings To Announce Annual Payout Increases In August
West Pharmaceutical: Q2 Earnings Suggest Recovery
Baron Asset Fund Q2 2025 Shareholder Letter
West Pharmaceutical Services Inc (WST)'s Winning Formula: Financial Metrics and Competitive ...
Best Dividend Aristocrats For August 2025